Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer

Xiaolong Zou,Haiquan Qiao,Xian Jiang,Xuesong Dong,Hongchi Jiang,Xueying Sun

DOI: https://doi.org/10.1186/1423-0127-16-33

2008-12-25

Journal of Biomedical Sciences

Abstract:

What problem does this paper attempt to address?

Treatment of Brain Metastasis after Radical Nephrectomy for Renal Cell Carcinoma: Report of Eight Cases and Review of the Literature

Runchun Lu,Liang Li,Zhiqiang Yi,Yang

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2019.11.006

2019-01-01

Abstract:Objective To investigate the clinical features, treatments, and prognosis of brain metastasis after local resection for renal cell carcinoma. Methods Clinical data of patients with brain metastasis after nephrectomy for renal cell carcinoma at Peking University First Hospital between March 2005 and May 2019 were analyzed retrospectively. The patients were followed and survival curves were plotted. Results A total of eight patients were included in the study, including 5 males and 3 females aged 42-70 years old, with a median age of 63 years old. Brain metastasis occurred 7-103 months after the treatment of renal carcinoma, and the median time was 41 months. Eight patients received nine operations, and 10 intracranial metastases were resected. The follow-up time was 38-204 months, and the median follow-up time was 95 months. Three of the eight patients died. The total survival time after brain metastasis surgery was 6-86 months, and the median survival time was 23 months. Conclusion The prognosis of patients with brain metastases after nephrectomy for renal cell carcinoma is poor, and local resection combined with radiotherapy can achieve satisfactory local control and prolong survival in selected cases. Key words: Carcinoma, renal cell; Neoplasm metastasis; Surgical treatment; Targeted therapy; Radiation therapy
Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

Pia Paffenholz,Philipp Ivanyi,Jozefina Casuscelli,Ramona Stelmach,Melis Guer,Katrin Schlack,Christopher Darr,Emily Rinderknecht,Thomas Hilser,Luka Flegar,Melanie Klee,Daniel Seidl,Analena Handke,Tim Nestler,Angelika Mattigk,Marinela Augustin,Sameh Hijazi,Marc Rehlinghaus,Axel Heidenreich,Viktor Gruenwald,

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.387

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:387 Background: Brain (BM) and bone metastases (BOM) in renal cell carcinoma (RCC) are associated with poor outcome. We evaluated real-world treatment paradigms of RCC patients with BM and BOM. Methods: We retrospectively analyzed RCC patients with BM and/or BOM treated at 18 German tertiary cancer centres from 2003 to 2023. Adverse events (AE) were reported according to CTCAE 5.0, objective response rate (ORR) according to local standard. Overall survival (OS) was calculated from start of treatment to progression or death, respectively and determined by KM plots. Results: We included 453 patients with a median age of 64 years (IQR 56-71). 93% of all patients had BOM, 15% BM and 8% both. Most patients (79%) had clear cell RCC, 7% of all patients had sarcomatoid differentiation. 82% of patients had an ECOG PS of 0/1. IMDC risk was favorable/intermediate/poor in 20/56/24%. 64% received prior nephrectomy. Patients with BOM received first-line IO-combinations in 61% (IO-IO: 38%, TKI-IO: 62%), TKI-monotherapy in 39%, while patients with BM received IO-combinations in 68% (IO-IO: 37%, TKI-IO: 63%) and TKI in 32%. IO-based first-line therapy increased from 2003 to 2023. AE of all grades occurred in 87% and 69% during IO-based therapy or TKI monotherapy, and CTCAE grade ≥ 3 in 42% or 25%. Best ORR and survival outcomes with median follow-up of 23 months (IQR 9-42) are described in table 1. 56% and 58% of all patients with BOM and BM received second-line treatment, with Cabozantinib (34%; 34%) and Nivolumab (17%, 23%) being the most common treatment options. In the subgroup of RCC with sarcomatoid features (n=36), 34 patients had BOM and 7 had BM, of which were treated with IO-combinations in 88% (BOM; IO-IO: 41%, TKI-IO: 59%) or 66% (BM; IO-IO: 50%, TKI-IO: 50%) and TKI-monotherapy in 12% (BOM) or 34% (BM) of all patients. Response rates (ORR/SD/PD) were 48%/28%/24% for IO-based therapy and 0%/50%/50% for TKI-monotherapy in RCC with sarcomatoid features, mOS was 41 months (95% CI 16.7-65.3). Conclusions: RCC patients with BOM and BM are increasingly treated with IO-combinations but lead to higher rates of AE grade ≥ 3. In patients with BOM, IO-TKI revealed higher ORR compared to IO-IO combination, but not in patients with BM. However, the small sample size and retrospective design are major limitations of our analysis. Prospective studies evaluating treatment options for BOM and BM in patients with RCC is critical. [Table: see text]

oncology
Turfgrass Root Basics

J. B. Beard

Abstract:P turfgrasses are characterized by an extremely fine, fibrous root system. This leads to considerable frustration on the part of researchers due to the time-consuming, costly procedures required to accurately study and measure turfgrass roots. Nevertheless, the monitoring of rooting depth and functional viability on a regular basis is an important dimension in any turf manager's information assemblage for key decision-making activities. Roots are a hidden, but major component of a turfgrass plant. Roots function in water absorption, nutrient uptake, anchorage, and sod strength. Actually, the unique, extensive, fibrous root system of turfgrass has a extraordinary ability to take up nutrient elements, and thereby protects the quality of groundwater. Turfgrass shoots/leaves have their meristematic region and allied cell division and elongation activities located at the base. Thus, the leaf tip is the oldest portion of the leaf and the leaf base the youngest. As a result the oldest part of the leaf is cut off during mowing. Just the opposite exists for roots, where the tip of the root most distant from the originating turfgrass crown or stem node region is the youngest part of the root. Thus, in harvesting sod the meristems or growing tips of the roots are cut off. Consequently, new root initiation must originate from the meristematic tissues in the crowns and the nodes on lateral stems, such as stolons and rhizomes. This basic principal dictates that the shallower the soil depth cut during sod harvesting, the more rapid the rate of sod transplant rooting, assuming there is no water stress. The principle sites through which water and nutrients are taken up from the soil solution into the roots and translocated upward to the shoots are via the root hairs. These are very delicate, whitish, outward extensions of individual epidermal or surface root cells. These root hairs are microscopic and thus cannot be seen by the naked eye. However, the surface area of these roots is 5 to 10 times greater than the primary and secondary root system that is visible to the eye. Therefore, understanding how environmental factors, cultural practices, and chemicals affect root hairs is a major concern in relation to maximizing the ability of turfgrasses to take up vital water and nutrients. Most turfgrasses are perennials, but certain perennial species have root systems that behave as an annual. Included among the annual-type root systems are such coolseason turfgrasses as perennial ryegrass (Lolium perenne), bentgrass (Agrostis spp.), and rough bluegrass (Poa trivialis). The critical period in the loss of root systems of cool-season turfgrasses is during mid-summer when soil temperatures at a 4-inch (100 mm) depth exceed 80°F (17°C) (Figure 1). Warm-season turfgrasses may be characterized as having annual root systems on occasions when spring root decline (SRD) occurs. The critical time in terms of a limited root system for warm-season turfgrasses is in the spring when soil temperatures at a 4-inch (100-mm) depth reach 64°F (18°C) (Figure 2). The genetic rooting ability of various turfgrass species and cultivars in terms of depth and mass varies considerably (Table 1). They range from very deep-rooted species, such as the bermudagrasses (Cynodon spp.), with a depth of 7 to 8 feet (2.1-2.4 m) under mowed conditions, to the shallow root systems of the zoysiagrasses (Zoysia spp.), American buffalograss (Buchloe dactyloides), and
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Kosuke Takemura,Audreylie Lemelin,Matthew S Ernst,J Connor Wells,Renee Maria Saliby,Talal El Zarif,Chris Labaki,Naveen S Basappa,Bernadett Szabados,Thomas Powles,Ian D Davis,Lori A Wood,Aly-Khan A Lalani,Rana R McKay,Jae-Lyun Lee,Luis Meza,Sumanta K Pal,Frede Donskov,Takeshi Yuasa,Benoit Beuselinck,Georges Gebrael,Neeraj Agarwal,Toni K Choueiri,Daniel Y C Heng,Matthew S. Ernst,J. Connor Wells,Naveen S. Basappa,Ian D. Davis,Lori A. Wood,Aly-Khan A. Lalani,Rana R. McKay,Sumanta K. Pal,Toni K. Choueiri,Daniel Y.C. Heng

DOI: https://doi.org/10.1016/j.eururo.2024.01.006

IF: 24.267

2024-01-01

European Urology

Abstract:Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated with longer median overall survival (OS; 32.7 mo, 95% confidence interval [CI] 22.3-not reached) versus tyrosine kinase inhibitor monotherapy (20.6 mo, 95% CI 15.7-24.5; p = 0.019), as were intensive focal therapies with stereotactic radiotherapy or neurosurgery (31.4 mo, 95% CI 22.3-37.5) versus whole-brain radiotherapy alone or no focal therapy (16.5 mo, 95% CI 10.2-21.1; p = 0.028). On multivariable analysis, IO-based regimens (HR 0.49, 95% CI 0.25-0.97; p = 0.040) and stereotactic radiotherapy or neurosurgery (HR 0.48, 95% CI 0.29-0.78; p = 0.003) were independently associated with longer OS, as was IMDC favorable or intermediate risk (HR 0.40, 95% CI 0.24-0.66; p < 0.001). Intensive systemic and focal therapies were associated with better prognosis in this population. Further studies should explore the clinical effectiveness of multimodal strategies. PATIENT SUMMARY: In a large group of patients with advanced kidney cancer, we found that 8.1% had brain metastases when starting systemic therapy. Patients with brain metastases had significantly poorer prognosis than those without brain metastases. Receipt of combination immunotherapy, stereotactic radiotherapy, or neurosurgery was associated with longer overall survival.

urology & nephrology
The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer

Sophie H. A. E. Derks,Edgar L. van der Meer,Arjen Joosse,Maja J. A. de Jonge,Cleo Slagter,Joost W. Schouten,Esther Oomen‐de Hoop,Marion Smits,Martin J. van den Bent,Joost L. M. Jongen,Astrid A. M. van der Veldt

DOI: https://doi.org/10.1002/ijc.34984

2024-05-05

International Journal of Cancer

Abstract:What's New? Brain metastasis (BM) affects a significant proportion of patients with metastatic renal cell carcinoma (mRCC). Little is known, however, about ways in which different mRCC treatment strategies impact BM development. Here, the authors investigated the timing of BM during different treatment strategies in a real‐world cohort of mRCC patients at the Erasmus MC Cancer Institute in the Netherlands. Active surveillance (AS) was a common initial strategy for mRCC. However, systemic treatment was more effective in potentially delaying metastasis to the brain. The findings imply a need for careful AS evaluation and a possible benefit to early initiation of systemic mRCC treatment. A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments have shown efficacy in mRCC, active surveillance (AS) is still commonly used in clinical practice. In this single‐center cohort study, we assessed the impact of different initial treatment strategies for metastatic RCC (mRCC) on the development of BM. All consecutive patients diagnosed with mRCC between 2011 and 2022 were included at the Erasmus MC Cancer Institute, the Netherlands, and a subgroup of patients with BM was selected. In total, 381 patients with mRCC (ECM, BM, or both) were identified. Forty‐six patients had BM of whom 39 had metachronous BM (diagnosed ≥1 month after ECM). Twenty‐five (64.1%) of these 39 patients with metachronous BM had received prior systemic treatment for ECM and 14 (35.9%) patients were treatment naive at BM diagnosis. The median BM‐free survival since ECM diagnosis was significantly longer (p = .02) in previously treated patients (29.0 [IQR 12.6–57.0] months) compared to treatment naive patients (6.8 [IQR 1.0–7.0] months). In conclusion, patients with mRCC who received systemic treatment for ECM prior to BM diagnosis had a longer BM‐free survival as compared to treatment naïve patients. These results emphasize the need for careful evaluation of treatment strategies, and especially AS, for patients with mRCC.

oncology
Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Zhenfei Xiang,Jun Chen,Huanle Zhang,Li Shen,Qichun Wei

DOI: https://doi.org/10.1159/000371501

2015-01-01

Oncology Research and Treatment

Abstract:Background: The prognostic factors for patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy (WBRT)-based combined modality therapy were investigated. Materials and Methods: Out of 135 patients treated with WBRT, 47 (34.8%) received a radiation boost, 84 (62.2%) underwent systemic chemotherapy, and 39 (28.9%) were given epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Results: The mean survival time was 9.3 months, and the 1-year and 2-year survival rates were 46.3 and 16.1%, respectively. In univariate analysis, improved survival was associated with age < 60 years, no extracranial metastasis, Karnofsky performance score ≥ 70, ≥ 3 cycles of chemotherapy after diagnosis of brain metastases, combined treatment with EGFR-TKIs, and no metastases in the cerebellum. In multivariate analysis, the above prognostic factors maintained significance with the exception of age. In an additional analysis of the 58 patients with 1-3 brain metastases, combination of WBRT with radiation boost was associated with better survival. Conclusion: We confirm previously described prognostic factors. Moreover, we found the absence of cerebellar metastases to be an independent prognostic factor for favorable outcome.
Atypical esophagitis.

H. Neumann,D. Kuester,K. Mönkemüller

DOI: https://doi.org/10.1053/j.gastro.2009.02.082

IF: 29.4

Gastroenterology

Abstract:
Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma.

Zhi-Bin Ke,Shao-Hao Chen,Ye-Hui Chen,Yu-Peng Wu,Fei Lin,Xue-Yi Xue,Qing-Shui Zheng,Ning Xu,Yong Wei

DOI: https://doi.org/10.1155/2020/6836234

2020-01-01

BioMed Research International

Abstract:Background. Patients with brain metastases (BM) from renal cell carcinoma (RCC) were considered to experience a poor prognosis. However, there is little knowledge on the risk factors for BM from RCC at diagnosis. This study was aimed at exploring the risk factors for patients with BM from RCC and the interaction among these risk factors. Methods. A total of 38759 cases of RCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Risk factors for BM from RCC were evaluated by univariate and multivariate logistic regression analyses. Interaction effect between age and tumor size was tested. Results. There was a significant difference in univariate analysis, including T stage, tumor size, grades III and IV, lymph node metastasis, bone metastasis, liver metastasis, lung metastasis, and surgery. There was a significant difference in multivariate analysis, including age, T stage, tumor size<10 cm, grade IV, lymph node metastasis, bone metastasis, lung metastasis, and surgery. Patients older than 70 had 0.653-fold lower risk of developing BM compared with those younger than 70. Patients with tumor size >= 4 cm and those<4 cm. The larger the tumor size, the higher the incidence of BM from RCC in those whose tumor size was less than 10 cm. An interaction test between the tumor size and age on brain metastasis was statistically significant in the crude analysis (P=0.0114) and model II analysis (P=0.0248) but not in model I analysis (P=0.1136). Although age significantly affected the risk of BM from RCC, impact of age on the risk of developing BM from RCC was limited to patients with tumor size >= 7 cm. Conclusion. Both tumor size and age were independent risk factors for brain metastases in patients with RCC. The impact of age on the risk of developing BM from RCC was limited to patients with tumor size >= 7 cm. Patients with a larger tumor size and younger age might have the higher risk of developing BM at diagnosis of RCC.
Prognostic Factors and Multidisciplinary Treatment Modalities for Brain Metastases from Colorectal Cancer: Analysis of 93 Patients.

Xiao-Dong Gu,Yan-Tao Cai,Yi-Ming Zhou,Zhen-Yang Li,Jian-Bin Xiang,Zong-You Chen

DOI: https://doi.org/10.1186/s12885-015-1933-2

IF: 4.638

2015-01-01

BMC Cancer

Abstract:BACKGROUND:The purpose of this study was to review patient characteristics and evaluate the potential factors affecting prognosis in cases of brain metastasis (BM) from colorectal cancer (CRC).METHODS:We retrospectively reviewed 93 cases of BM from CRC in our hospital. Patient demographics, neurologic symptoms, and location and number of BMs were recorded. Factors analyzed included: age; sex; Karnofsky performance score; number of BMs; presence of extracranial metastases; dimensions; location of tumors; treatment modalities.RESULTS:The overall 1- and 2-year survival rates were 27.7 and 9.9%. On multivariate analysis, the number of BMs, extracranial metastases and the initial treatment modalities were found to be independent prognostic factors for overall survival. Patients treated with surgical resection followed by WBRT or SRS had an improved prognosis relative to those treated with surgery alone (P=0.02 and P=0.02, respectively). No significance difference in survival rate was found between patients treated with SRS alone or SRS plus WBRT (P=0.11).CONCLUSIONS:Surgical resection of BMs from CRC in selected patients may help prolong survival. Additional radiotherapy following surgery is valuable in improving prognosis. Extracranial metastasis, multiple BM lesions and initial non operation can be considered as independent factors associated with poor prognosis.
Reliability of Common Prognostic Parameters and Indices

Julian Mangesius,Thomas Seppi,Christoph Reinhold Arnold,Stephanie Mangesius,Johannes Kerschbaumer,Matthias Demetz,Danijela Minasch,Samuel Moritz Vorbach,Manuel Sarcletti,Peter Lukas,Meinhard Nevinny-Stickel,Ute Ganswindt

DOI: https://doi.org/10.3390/curroncol31040132

2024-03-27

Current Oncology

Abstract:This study aims to evaluate the clinical outcome of stereotactic radiosurgery as the sole treatment for brain metastases and to assess prognostic factors influencing survival. A total of 108 consecutive patients with 213 metastases were retrospectively analyzed. Treatment was determined with close-meshed MRI follow-up. Various prognostic factors were assessed, and several prognostic indices were compared regarding their reliability to estimate overall survival. Median overall survival was 15 months; one-year overall survival was 50.5%. Both one- and two-year local controls were 90.9%. The rate of new metastases after SRS was 49.1%. Multivariate analysis of prognostic factors revealed that the presence of extracranial metastases, male sex, lower KPI, and progressive extracranial disease were significant risk factors for decreased survival. Of all evaluated prognostic indices, the Basic Score for Brain Metastases (BSBMs) showed the best correlation with overall survival. A substantial survival advantage was found for female patients after SRS when compared to male patients (18 versus 9 months, p = 0.003). SRS of brain metastasis is a safe and effective treatment option when frequent monitoring for new metastases with MRI is performed. Common prognostic scores lack reliable estimation of survival times. Female sex should be considered as an additional independent positive prognostic factor influencing survival.

oncology
Surgical treatment for brain metastases: prognostic factors and survival in 177 patients

Andreas M. Stark,Hauke Tscheslog,Ralf Buhl,Janka Held-Feindt,H. Maximilian Mehdorn

DOI: https://doi.org/10.1007/s10143-004-0364-3

IF: 2.8

2004-12-18

Neurosurgical Review

Abstract:Brain metastases are an increasingly frequent complication of cancer. Advances in diagnosis and treatment have led to wider indications for surgery. We present a single-institution series of 177 patients and discuss our results with regard to the literature. Special focus is on patients with advanced age, multiple brain metastases, extracranial metastases, and brain metastasis recurrence. All patients underwent craniotomy for the resection of solid tumor brain metastases between 1994 and 2001 in our department. Perioperative morbidity and mortality as well as survival were evaluated. The median patient age was 59 years (range 32–86 years). In 177 patients, 348 brain metastases were detected, of which 68.0% were supratentorial and 32.0% were infratentorial. According to univariate analysis, the following parameters were significantly associated with prolonged patient survival: (1) age <70 years, (2) one to three intracranial metastases, (3) favorable postoperative performance, (4) resection of all intracranial lesions, and (5) recraniotomy for brain metastasis recurrence. In contrast, the presence of extracranial metastases, metachronous diagnosis, and solitary brain metastases had no influence on survival. As expected, younger age and limited number of brain metastases (up to three) are favorable prognostic factors. Remarkably, the presence of extracranial metastases had no influence on patient survival.

surgery,clinical neurology
Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors

L Hahnemann,A Krämer,C Fink,C Jungk,M Thomas,P Christopoulos,J W Lischalk,J Meis,J Hörner-Rieber,T Eichkorn,M Deng,K Lang,A Paul,E Meixner,F Weykamp,J Debus,L König

DOI: https://doi.org/10.1016/j.ctro.2024.100782

2024-04-21

Abstract:Background and purpose: After surgical resection of brain metastases (BM), radiotherapy (RT) is indicated. Postoperative stereotactic radiosurgery (SRS) reduces the risk of local progression and neurocognitive decline compared to whole brain radiotherapy (WBRT). Aside from the optimal dose and fractionation, little is known about the combination of systemic therapy and postoperative fractionated stereotactic radiotherapy (fSRT), especially regarding tumour control and toxicity. Methods: In this study, 105 patients receiving postoperative fSRT with 35 Gy in 7 fractions performed with Cyberknife were retrospectively reviewed. Overall survival (OS), local control (LC) and total intracranial brain control (TIBC) were analysed via Kaplan-Meier method. Cox proportional hazards models were used to identify prognostic factors. Results: Median follow-up was 20.8 months. One-year TIBC was 61.6% and one-year LC was 98.6%. Median OS was 28.7 (95%-CI: 16.9-40.5) months. In total, local progression (median time not reached) occurred in 2.0% and in 20.4% radiation-induced contrast enhancements (RICE) of the cavity (after median of 14.3 months) were diagnosed. Absence of extracranial metastases was identified as an independent prognostic factor for superior OS (p = <0.001) in multivariate analyses, while a higher Karnofsky performance score (KPS) was predictive for longer OS in univariate analysis (p = 0.041). Leptomeningeal disease (LMD) developed in 13% of patients. Conclusion: FSRT after surgical resection of BM is an effective and safe treatment approach with excellent local control and acceptable toxicity. Further prospective randomized trials are needed to establish standardized therapeutic guidelines.
NCMP-02. RENAL CELL CARCINOMA WITH METASTASIS TO THE CHOROID PLEXUS

Emily Kim,Danial Nadeem,James Nguyen,Hussam Ammar

DOI: https://doi.org/10.1093/neuonc/noac209.730

2022-11-01

Neuro-Oncology

Abstract:Abstract BACKGROUND Intraventricular brain tumors make up only 0.9–4.5% of all cases of metastatic brain cancer.1 Involvement of the choroid plexus (CP) is even rarer with only a handful of documented cases. 2,3 Here we describe a case of bilateral multifocal metastasis to the choroid plexus appearing 10 years after nephrectomy in a male with stage IV renal cell carcinoma (RCC). CASE PRESENTATION: Our patient is a 74-year-old male with stage IV RCC diagnosed in 2006 and treated with radical nephrectomy and immunotherapy in 2011. In 2020, he presented to the emergency department with altered mental status. Brain magnetic resonance imaging (MRI) revealed an enhancing hemorrhagic lesion in the trigone of the right lateral ventricle (LV) and nodular thickening in the center of the right LV and trigone of the left LV, suggestive of metastatic disease. In 2021, the patient developed refractory seizures, and serial MRIs showed disease progression. He underwent several craniotomies with pathology confirming metastatic clear cell carcinoma, consistent with a renal primary. In 2022, the patient again presented with altered mental status. MRI revealed new avidly enhancing subcentimeter solid nodules in the CP of both LVs consistent with metastatic disease. Per the wishes of the family, palliative measures were pursued, and the patient was discharged home. CONCLUSION RCC can reappear several years after nephrectomy. 4 Metastatic RCC appears to have a unique propensity to spread to the ventricular system and the CP, which indicates late progression of disease. 1,5,6 While surgery may be viable if tumor burden is low, therapeutic options are limited in the advanced disease stages, as in our patient. Palliative care should be offered early to maximize remaining quality of life.

oncology,clinical neurology
Enhancing outcomes: neurosurgical resection in brain metastasis patients with poor Karnofsky performance score - a comprehensive survival analysis

Maria Goldberg,Michel G. Mondragon-Soto,Ghaith Altawalbeh,Lea Baumgart,Jens Gempt,Denise Bernhardt,Stephanie E. Combs,Bernhard Meyer,Amir Kaywan Aftahy

DOI: https://doi.org/10.3389/fonc.2023.1343500

IF: 4.7

2024-01-11

Frontiers in Oncology

Abstract:Background: A reduced Karnofsky performance score (KPS) often leads to the discontinuation of surgical and adjuvant therapy, owing to a lack of evidence of survival and quality of life benefits. This study aimed to examine the clinical and treatment outcomes of patients with KPS < 70 after neurosurgical resection and identify prognostic factors associated with better survival. Methods: Patients with a preoperative KPS 3 months was considered favorable and ≤ 3 months as poor. Results: A total of 140 patients were identified. Median overall survival was 5.6 months (range 0-58). There was no difference in the preoperative KPS between the groups of > 3 and ≤ 3 months (50; range, 20–60 vs. 50; range, 10–60, p = 0.077). There was a significant improvement in KPS after surgery in patients with a preoperative KPS of 20% (20 vs 40 ± 20, p = 0.048). In the other groups, no significant changes in KPS were observed. Adjuvant radiotherapy was associated with better survival (44 [84.6%] vs. 32 [36.4%]; hazard ratio [HR], 0.0363; confidence interval [CI], 0.197–0.670, p = 0.00199). Adjuvant chemotherapy and immunotherapy resulted in prolonged survival (24 [46.2%] vs. 12 [13.6%]; HR 0.474, CI 0.263–0.854, p = 0.013]. Systemic disease progression was associated with poor survival (36 [50%] vs. 71 [80.7%]; HR 5.975, CI 2.610–13.677, p < 0.001]. Conclusion: Neurosurgical resection is an appropriate treatment modality for patients with low KPS. Surgery may improve functional status and facilitate further tumor-specific treatment. Combined treatment with adjuvant radiotherapy and systemic therapy was associated with improved survival in this cohort of patients. Systemic tumor progression has been identified as an independent factor for a poor prognosis. There is almost no information regarding surgical and adjuvant treatment in patients with low KPS. Our paper provides novel data on clinical outcome and survival analysis of patients with BM who underwent surgical treatment.

oncology
Cytoreduction of Residual Tumor Burden Is Decisive for Prolonged Survival in Patients with Recurrent Brain Metastases—Retrospective Analysis of 219 Patients

Jonas Lin,Yannik Kaiser,Benedikt Wiestler,Denise Bernhardt,Stephanie E. Combs,Claire Delbridge,Bernhard Meyer,Jens Gempt,Amir Kaywan Aftahy

DOI: https://doi.org/10.3390/cancers15205067

2023-10-20

Cancers

Abstract:Background: Despite advances in treatment for brain metastases (BMs), the prognosis for recurrent BMs remains poor and requires further research to advance clinical management and improve patient outcomes. In particular, data addressing the impact of tumor volume and surgical resection with regard to survival remain scarce. Methods: Adult patients with recurrent BMs between December 2007 and December 2022 were analyzed. A distinction was made between operated and non-operated patients, and the residual tumor burden (RTB) was determined by using (postoperative) MRI. Survival analysis was performed and RTB cutoff values were calculated using maximally selected log-rank statistics. In addition, further analyses on systemic tumor progression and (postoperative) tumor therapy were conducted. Results: In total, 219 patients were included in the analysis. Median age was 60 years (IQR 52–69). Median preoperative tumor burden was 2.4 cm3 (IQR 0.8–8.3), and postoperative tumor burden was 0.5 cm3 (IQR 0.0–2.9). A total of 95 patients (43.4%) underwent surgery, and complete cytoreduction was achieved in 55 (25.1%) patients. Median overall survival was 6 months (IQR 2–10). Cutoff RTB in all patients was 0.12 cm3, showing a significant difference (p = 0.00029) in overall survival (OS). Multivariate analysis showed preoperative KPSS (HR 0.983, 95% CI, 0.967–0.997, p = 0.015), postoperative tumor burden (HR 1.03, 95% CI 1.008–1.053, p = 0.007), and complete vs. incomplete resection (HR 0.629, 95% CI 0.420–0.941, p = 0.024) as significant. Longer survival was significantly associated with surgery for recurrent BMs (p = 0.00097), and additional analysis demonstrated the significant effect of complete resection on survival (p = 0.0027). In the subgroup of patients with systemic progression, a cutoff RTB of 0.97 cm3 (p = 0.00068) was found; patients who had received surgery also showed prolonged OS (p = 0.036). Single systemic therapy (p = 0.048) and the combination of radiotherapy and systemic therapy had a significant influence on survival (p = 0.036). Conclusions: RTB is a strong prognostic factor for survival in patients with recurrent BMs. Operated patients with recurrent BMs showed longer survival independent of systemic progression. Maximal cytoreduction should be targeted to achieve better long-term outcomes.

oncology
P11.11.B Stereotactic radiosurgery for brain metastases;outcome and prognostic factors in patients treated with single-fraction and multiple-fractions

S Lukacova,K B Kristoffersen,J F Kallehauge,L N Bentzen,C S Byskov,A Trip

DOI: https://doi.org/10.1093/neuonc/noac174.200

2022-09-01

Neuro-Oncology

Abstract:Abstract Background Stereotactic radiosurgery (SRS) is preferred to whole brain radiotherapy (WBRT) for the treatment of patients with a limited number of brain metastases, both as primary treatment and after surgery. SRS can be delivered in a single fraction (SF) or in multiple fractions (MF) depending on tumor size and location. The aim of this single-center retrospective study was to evaluate intracranial control and overall survival (OS) in patients who received SF and MF SRS for brain metastases. Material and Methods All patients treated with primary SRS for brain metastases at Aarhus University Hospital between 2015 and 2020 were identified. Independent of undergoing surgery, SF SRS (20 Gy) was administered for targets (gross tumor volume) <2 cm in diameter and MF SRS (24-27 Gy in 3 fractions) for targets >2 cm. SRS was not combined with WBRT. Treatment response was evaluated by 3-monthly MRI-scan. To evaluate intracranial control, first events were scored as local-only failure (tumor progression at the SRS treatment site), distant failure (tumor progression not at the SRS site), and combined failure (local and distant failure). Actuarial incidence of local failure (local-only and combined) and OS were estimated using the Kaplan-Meier method. To analyze the association of SF and MF SRS with local failure and OS, multivariable Cox regression analyses were used. Results The consecutive cohort consisted of 196 patients treated for 275 brain metastases. The most frequent primary disease was non-small cell lung cancer (NSCLC n=96), followed by renal cell carcinoma (n=26) and breast cancer (n=22). SRS was delivered to 1 (n=133), 2 (n=49), 3 (n=12), and 4 (n=2) targets per patient. SF and MF SRS was used in 99 (51%) and 97 (49%) patients, respectively. In 40 patients, SRS was administered after surgery (SF n=7, MF n=33). At a median (range) follow-up of 10 (0-93) months, 111 (57%) patients had intracranial progression, and 159 (81%) patients died. Local-only/distant/combined failure rate was 23 and 42%/59 and 35%/18 and 23%, in SF and MF SRS respectively. The median time to local failure was respective 9.0 (95% CI 5.4-12.6) and 6.0 (95% CI 5.0-7.0) months in the SF and MF SRS group. SF SRS and surgery were independently associated with a longer time to local failure. Salvage WBRT, SRS, and re-operation were performed in respective 36, 13, and 26 patients. Histopathological radiation necrosis was observed in 5 patients. All patients with necrosis had a primary diagnosis of NSCLC, and 4/5 patients were treated with SF SRS. For the total group, the median OS was 10.0 (95% CI 8.0 - 12.0) months. PS<2, surgery, stable extracranial disease and SF SRS were associated with a longer survival. Conclusion MF SRS was associated with a higher rate of and shorter time to local failure, and was a poor prognostic factor for survival, which is in line with the selection of patients with more unfavorable brain metastases for this treatment.

oncology,clinical neurology
Results of Treatment of Patients with Non-Small Cell Lung Cancer with Metastatic Brain Lesions

П.Е. Короткевич,C.Н. Пивоварчик,А.Н. Фиалко,О.И. Быданов

DOI: https://doi.org/10.34883/pi.2021.9.4.021

2022-01-13

Евразийский онкологический журнал

Abstract:Введение. Головной мозг (ГМ) является одной из наиболее частых областей для метастазирования при немелкоклеточном раке легкого (НМРЛ). Наличие метастазов в ГМ сопряжено с неблагоприятным прогнозом, являясь жизнеугрожающим состоянием, требующим немедленного принятия решения о тактике лечения.Цель. Изучение результатов лечения пациентов с НМРЛ с метастатическим поражением ГМ. Материалы и методы. Это ретроспективное исследование, включающее 111 последовательных случаев морфологически верифицированного НМРЛ с метастатическим поражением ГМ за период с 2018 по 2020 г. Проанализированы результаты лечения в 2 группах пациентов: 1 – с первичным метастатическим поражением ГМ (n=46); 2 – с прогрессированием в ГМ после ранее проведенного лечения (n=65).Результаты. В первой группе однолетняя общая выживаемость составила 22±6%, медиана общей выживаемости – 4 месяца. Данные мультивариантного анализа свидетельствуют о том, что наличие множественных метастазов в ГМ и отсутствие локального лечения в 6,75 раза увеличивают риск смерти (p=0,0001). Наличие экстракраниальных метастазов негативно сказывается на прогнозе, в 2,18 раза увеличивая риск смерти пациентов с метастатическим поражением ГМ (p=0,0294).Во второй группе медиана времени до прогрессирования в ГМ составила 1,08 года. Риск прогрессирования в ГМ был достоверно выше у пациентов с местнораспространенным и метастатическим раком легкого, получивших паллиативное лечение (p=0,0012). Медиана общей выживаемости после появления метастазов в ГМ составила 6 месяцев. Группа пациентов, получившая радикальное лечение по поводу метастазов в ГМ, характеризовалась лучшими показателями выживаемости (p=0,0173). Половина пациентов, получающих таргетную терапию, пережили 1 год.Выводы:1. Учитывая высокую частоту метастатического поражения ГМ при НМРЛ целесообразно обследование ГМ у всех пациентов, подлежащих радикальному лечению, за исключением I-A стадии.2. Так как продолжительность жизни пациентов в первую очередь определяется метастатическим поражением ГМ, а облучение всего мозга характеризуется низкой эффективностью, всегда следует рассматривать возможность радикального лечения (хирургическое удаление, радиохирургия и их комбинация) даже у пациентов с наличием экстракраниальных метастазов.3. У пациентов с метастатической аденокарциномой легкого, в том числе с поражением ГМ, необходимо проводить молекулярно-генетическое исследование опухоли. При выявлении активирующих мутаций рассматривать вопрос о назначении таргетной терапии, так как на сегодняшний день в арсенале онкологов имеются препараты, хорошо проникающие через гематоэнцефалический барьер и характеризующиеся высокой эффективностью при метастатическом поражении ГМ даже без локального лечения. Introduction. The brain is one of the most common areas for metastasis in non-small cell lung cancer (NSCLC). The presence of metastases in the brain is associated with a poor prognosis, being a life-threatening condition that requires an immediate decision on treatment tactics.The purpose of our study was to study the results of treatment of patients with NSCLC with metastatic brain lesions, depending on prognostic factors.Materials and methods. This is a retrospective study that included 111 consecutive cases ofmorphologically verified NSCLC living in the Minsk region with diagnosed metastatic brain lesions for the period from 2018 to 2020. The results of treatment in 2 groups of patients were analyzed: 1 – with primary metastatic brain lesion (n=46); 2 – with progression to the brain after previous treatment (n=65).Results. In the first group, the one-year overall survival rate was 22±6%, the median overall survival rate was 4 months. Multivariate analysis data indicate that the presence of multiple brain metastases and the absence of local treatment increase the risk of death by 6.75 times (p=0.0001). The presence of extracranial metastases negatively affects the prognosis by a 2.18-fold increase in the risk of death in patients with metastatic brain lesions (p=0.0294).In the second group, the median time to progression to the brain was 1.08 years. The risk of progression to the brain was significantly higher in patients with locally advanced and metastatic lung cancer who received palliative treatment (p=0.0012). The median overall survival after the onset of brain metastases was 6 months. The group of patients who received conditionally radical treatment was characterized by the best survival rates (p=0.0173). Half of the patients receiving targeted therapy survived 1 year.Conclusions:1. Given the high incidence of metastatic brain lesions in NSCLC, it is advisable to examine the brain in all patients subject to radical treatment, with the exception of stage IA.2. Since the life expectancy of patients is primarily determined by metastatic brain lesions, and irradiation of the whole brain is characterized by low efficiency, the possibility of radical treatment (surgical removal, radiosurgery, and their combination) should always be considered, even in patients with extracranial metastases.3. In patients with metastatic adenocarcinoma of the lung, including those with brain damage, it is necessary to conduct a molecular genetic study of the tumor. When detecting activatingmutations, consider the appointment of targeted therapy, since today in the arsenal of oncologists there are drugs that penetrate well through the blood-brain barrier and are characterized by high efficiency in metastatic brain lesions even without local treatment.
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.

C. Franzese,L. Cozzi,F. De Rose,P. Navarria,M. Scorsetti,D. Franceschini,S. Tomatis,L. Toschi,L. Bello,F. Pessina,A. Santoro,A. Ascolese

DOI: https://doi.org/10.1259/bjr.20170022

2017-03-22

British Journal of Radiology

Abstract:OBJECTIVE To evaluate the outcome of patients with non-small-cell lung cancer (NSCLC) with limited brain metastases (BMs) treated with local approaches omitting whole-brain radiation therapy (WBRT). METHODS Surgery was performed in case of a single, large BM, controlled extracranial disease and Karnofsky Performance Status (KPS) 90-100; stereotactic radiosurgery (SRS) or hypofractionated stereotactic radiosurgery (HSRS) was performed in all other cases. The prescribed dose was 24 Gy/1 fraction for lesions <2.5 cm, and a median of 30 Gy (24-40 Gy) in 3-5 fractions for lesions >2.5 cm. RESULTS 156 patients treated for 228 BMs were retrospectively evaluated. The median age was 62 years. The majority of patients had a KPS 90-100, recursive partitioning analysis Class II, diagnosis-specific graded prognostic assessment score 2.5-3 and 1-2 BMs. Surgical resection was performed in 18 cases, and SRS/HSRS was performed in 210 cases. The 1-2-year local control was 87.2 ± 3.0% and 72.8 ± 5.0%; the 1.2-year brain distant failure was 30.8 ± 4.0% and 58.1 ± 6.0%; the 1-2-year overall survival was 60.9 ± 3.9% and 31.4 ± 4.0%. On univariate and multivariate analysis, the following factors influenced survival: age (p = 0.01), the presence of lymph node involvement (p = 0.03), KPS (p << 0.01), the presence of extracranial metastases at the time of BM treatment (p < 0.01), the number of BMs (p = 0.02) and the treatment performed (p < 0.01). CONCLUSION The choice of an adequate local treatment can impact on survival in patients with limited BMs from NSCLC. A careful evaluation of prognostic and predictive factors is a pivotal additional aid. Advances in knowledge: Radiosurgery or surgery followed by radiosurgery on the tumour bed in place of WBRT proved to be an effective treatment influencing outcome. Surgical resection followed by SRS on the tumour bed has to be considered for lesions ≥15 mm, in patients with good KPS, age ≤70 years, adenocarcinoma histology and oligometastatic disease.

Medicine
[Treatment and Prognosis of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Study].

Meina Wu,Xuyi Liu,Jian Fang,Tongtong An,Jie Wang

DOI: https://doi.org/10.3779/j.issn.1009-3419.2006.06.13

2006-01-01

Chinese Journal of Lung Cancer

Abstract:BACKGROUND:Now the treatment of non-small cell lung cancer (NSCLC) patients with brain metastasis is not a standard program. The aim of this study is to summarize the factors related to survival of patients with brain metastases from NSCLC.METHODS:A total of 111 NSCLC patients with brain metastases (from September 1995-May 2004) were defined as symptomatic group (37 patients) and asymptomatic group (74 patients) according to central nervous system (CNS) symptoms. The patients in the symptomatic group were given whole brain radiation therapy (WBRT, DT 30-40Gy/20f) first, and then received cisplatin-based chemotherapy. The patients in the asymptomatic group were given cisplatin-based chemotherapy first, and then received WBRT. During the treatment, 49 patients received chemotherapy of BCNU or VM-26 irregularly.RESULTS:The median survival time was 11 months. The 1-and 2-year survival rate was 40.79% and 13.26% respectively. The survival time was not significantly different between the symptomatic group and asymptomatic group. Median chemotherapy of asymptomatic group was 3 cycles (1-6 cycles) before WBRT. Those patients who received 3 or 4 cycles of chemotherapy before WBRT had better survival (P= 0.0188 , P=0.0035). The treatment of BCNU or VM-26 was a benefit factor for survival (P=0.0219) in asymptomatic group. The hematologic toxicity of grade III or IV was not significantly different between the two groups (P > 0.05). The number of brain metastasis (P=0.000), extracranial metastasis (P=0.022) and WHO performance status (P=0.001) were independent prognostic factors.CONCLUSIONS:The patients with asymptomatic brain metastases receive 3-4 cycles of chemotherapy before WBRT may be reasonable. During the therapy, the patients with administration of BCNU or VM-26 may have survival benefit.
Postoperative treatment and prognosis of patients with resected single brain metastasis: How useful are established prognostic scores?

Carsten Nieder,Sabrina T. Astner,Nikolaus H. Andratschke,Kirsten Marienhagen

DOI: https://doi.org/10.1016/j.clineuro.2010.09.009

IF: 1.885

2011-02-01

Clinical Neurology and Neurosurgery

Abstract:OBJECTIVE: To evaluate postoperative prognosis and the performance of known prognostic scores in patients treated with surgical resection for single brain metastasis.METHODS: We evaluated prognostic factors and five previously published prognostic scores in a group of 74 patients with single brain metastasis treated with surgery with or without immediate whole-brain radiotherapy (WBRT).RESULTS: In multivariate analysis, good performance status, absence of extracranial metastases and primary tumor control were significantly associated with improved overall survival. Survival (median 10.8 months) was not significantly prolonged by immediate WBRT. Salvage treatment was necessary in 87% of patients without immediate WBRT. All five scores identified groups of patients with superior prognosis. The recursive partitioning analysis (RPA) classes, the graded prognostic assessment (GPA) score and the score developed by Rades et al. identified a poor prognosis group, but the numbers of poor prognosis patients were very small.CONCLUSIONS: RPA and GPA appear to have the most utility in delineating exceptionally good or poor prognosis patients after resection of single brain metastasis, but this finding remains to be validated in a larger study population. Identification and validation of suitable prognostic scores hopefully will guide decision making regarding local treatment of solitary brain metastasis.

surgery,clinical neurology

Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer

Treatment of Brain Metastasis after Radical Nephrectomy for Renal Cell Carcinoma: Report of Eight Cases and Review of the Literature

Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

Turfgrass Root Basics

Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Atypical esophagitis.

Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma.

Prognostic Factors and Multidisciplinary Treatment Modalities for Brain Metastases from Colorectal Cancer: Analysis of 93 Patients.

Reliability of Common Prognostic Parameters and Indices

Surgical treatment for brain metastases: prognostic factors and survival in 177 patients

Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors

NCMP-02. RENAL CELL CARCINOMA WITH METASTASIS TO THE CHOROID PLEXUS

Enhancing outcomes: neurosurgical resection in brain metastasis patients with poor Karnofsky performance score - a comprehensive survival analysis

Cytoreduction of Residual Tumor Burden Is Decisive for Prolonged Survival in Patients with Recurrent Brain Metastases—Retrospective Analysis of 219 Patients

P11.11.B Stereotactic radiosurgery for brain metastases;outcome and prognostic factors in patients treated with single-fraction and multiple-fractions

Results of Treatment of Patients with Non-Small Cell Lung Cancer with Metastatic Brain Lesions

Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.

[Treatment and Prognosis of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Study].

Postoperative treatment and prognosis of patients with resected single brain metastasis: How useful are established prognostic scores?